We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Polyplus-transfection Raises EUR 1.2 Million through an Issue of Convertible Bonds
News

Polyplus-transfection Raises EUR 1.2 Million through an Issue of Convertible Bonds

Polyplus-transfection Raises EUR 1.2 Million through an Issue of Convertible Bonds
News

Polyplus-transfection Raises EUR 1.2 Million through an Issue of Convertible Bonds

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Polyplus-transfection Raises EUR 1.2 Million through an Issue of Convertible Bonds"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Polyplus-transfection has completed a new funding round in which it raised EUR 1.2 million. The funding took the form of an issue of convertible bonds and was led by existing investor CIC-Vizille Capital Innovation, with the participation of the company’s two other historic shareholders, Avenir Finance Gestion and CIC Finance-CIC Investissement Alsace.

These funds will be assigned primarily to the RNAplus research program, which has been approved by the "Innovations Thérapeutiques" competitivity cluster. The objective of the RNAplus project is to generate new oligonucleotides capable of silencing the expression of a target gene through RNA interference without the use of a delivery reagent.

Polyplus-transfection will also reinforce its human resources with a new CEO and a Business Development Manager in the United States, its leading market (40 percent of sales).

In addition, the funding will allow Polyplus to push ahead its program for exploiting ZNA (Zip Nucleic Acids) oligonucleotides and to defend the company’s intellectual property, especially its rights to the use of polyehtylenimine (PEI) for bioproduction purposes.
Advertisement